Enliven Therapeutics, Inc.
ELVN
$18.65
-$0.09-0.48%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -23.14% | -0.10% | -16.07% | 12.26% | -17.39% |
| Total Depreciation and Amortization | -7.50% | 0.00% | 2.56% | -1.27% | 1.28% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.74% | 8.69% | 54.28% | -2.85% | 192.20% |
| Change in Net Operating Assets | -389.41% | -110.22% | 213.78% | 5.42% | -184.83% |
| Cash from Operations | -40.25% | -41.09% | 40.33% | 12.53% | -87.16% |
| Capital Expenditure | -- | 100.00% | -1,000.00% | 90.00% | -42.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 99.04% | -95.10% | 144.11% | -88.43% | -146.16% |
| Cash from Investing | 96.29% | -95.10% | 144.04% | -88.23% | -146.23% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.41% | 3,478.51% | -38.15% | -98.00% | 100,200.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.41% | 3,478.51% | -38.15% | -98.00% | 100,200.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -195.62% | 526.56% | 107.17% | -206.67% | 86.45% |